Addex Therapeutics Says Partner J&J Innovative Medicine Discontinues Development of ADX71149 to Treat Epilepsy; Addex Shares Fall Pre-Bell
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Express News | Addex Therapeutics - Janssen Informed Co It Discontinued Development of Adx71149 (Jnj-40411813) in Epilepsy
J&J Ends Work on Addex Epilepsy Drug Candidate ADX71149: Report
Addex Therapeutics Unveils Breakthrough Cough Treatment
Addex Presents Positive Results From GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Addex Therapeutics Shareholders Greenlight Proposals
Addex Shareholders Approve All Resolutions at Annual General Meeting
Earnings Call Summary | Addex Therapeutics(ADXN.US) Q1 2024 Earnings Conference
Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript
Express News | Addex Therapeutics (ADXN.US): Q1 2024 revenue was $268,840, and the previous value was $542,430; EPS was -$1.37, and the previous value was -$5.20.
Addex Therapeutics GAAP EPS of -CHF 0.01, Revenue of CHF 0.24M
Addex Therapeutics Q1 Net Loss Widens, Income Drops
Addex Therapeutics Q1 EPS $(1.37) Up From $(5.20) YoY, Sales $268.83K Down From $542.43K YoY
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
When Can We Expect A Profit From Addex Therapeutics Ltd (VTX:ADXN)?
Addex to Present at Bio€quity Europe 2024
No Data